Antigen-specificity and DTIC before peptide-vaccination differently shape immune-checkpoint expression pattern, anti-tumor functionality and TCR repertoire in melanoma patients

Antigen-specificity and DTIC before peptide-vaccination differently shape immune-checkpoint expression pattern, anti-tumor functionality and TCR repertoire in melanoma patients

We have recently described that DNA-damage inducing drug DTIC, administered before peptide (Melan-A and gp100)-vaccination, improves anti-tumor CD8+ Melan-A-specific T-cell functionality, enlarges the Melan-A+ TCR repertoire and impacts the overall survival of melanoma patients. To identify whether...

Full description

Bibliographic Details
Main Authors: Belinda Palermo, Ornella Franzese, Cosmo Di Donna, Mariangela Panetta, Concetta Quintarelli, Isabella Sperduti, Novella Gualtieri, Maria Laura Foddai, Enrico Proietti, Virginia Ferraresi, Gennaro Ciliberto, Paola Nisticò
Format: Article
Language:English
Published: Taylor & Francis Group 2018-12-01
Series:OncoImmunology
Subjects:
chemo-immunotherapy
dacarbazine
human melanoma
gp100
melan-a
cd8+ t cells
pd-1
cd28
tcr diversity
clonotypes
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1465163

Internet

http://dx.doi.org/10.1080/2162402X.2018.1465163

Similar Items